Myhibbin Dosage

Generic name: MYCOPHENOLATE MOFETIL 200mg in 1mL
Dosage form: oral suspension
Drug class: Selective immunosuppressants

Medically reviewed by Drugs.com. Last updated on May 7, 2024.

Important Administration Instructions

MYHIBBIN should not be used without the supervision of a physician with experience in immunosuppressive therapy.

MYHIBBIN should not be used interchangeably with mycophenolic acid delayed-release tablets without supervision of a physician with experience in immunosuppressive therapybecause the rates of absorption following the administration of MYHIBBIN and mycophenolic acid delayed-release tablets are not equivalent.

Patients should avoid contact of the skin or mucous membranes with MYHIBBIN. If such contact occurs, they must wash the area of contact thoroughly with soap and water. In case of ocular contact, rinse eyes with plain water.

The initial oral dose of MYHIBBIN should be given as soon as possible following kidney, heart or liver transplant. It is recommended that MYHIBBIN be administered on an empty stomach. In stable transplant patients, however, MYHIBBIN may be administered with food if necessary. MYHIBBIN must not be mixed with any liquids prior to dose administration. If needed, MYHIBBIN can be administered via a nasogastric tube with a minimum size of 8 French (minimum 1.7 mm interior diameter).

Patients should be instructed to take a missed dose as soon as they remember, except if it is closer than 2 hours to the next scheduled dose; in this case, they should continue to take MYHIBBIN at the usual times.

Recommended Dosage for Kidney Transplant Patients

Adults

The recommended dosage for adult kidney transplant patients is 1 g orally, administered twice daily (total daily dose of 2 g).

Pediatrics Patients 3 months and older

Pediatric dosing is based on body surface area (BSA). The recommended dosage for pediatric kidney transplant patients 3 months and older is 600 mg/m 2, administered twice daily (maximum daily dose of 2 g or 10 mL of the oral suspension).

Recommended Dosage for Heart Transplant Patients

Adults

The recommended dosage for adult heart transplant patients is 1.5 g orally administered twice daily (total daily dose of 3 g).

Pediatric Patients 3 months and older

The recommended starting dosage for pediatric heart transplant patients 3 months and older is 600 mg/m 2, administered twice daily. If well tolerated, the dose can be increased to a maintenance dosage of 900 mg/m 2administered twice daily (maximum total daily dose of 3 g or 15 mL of the oral suspension). The dose may be individualized based on clinical assessment.

Recommended Dosage for Liver Transplant Patients

Adults

The recommended dosage for adult liver transplant patients is 1.5 g administered orally twice daily (total daily dose of 3 g).

Pediatrics Patients 3 months and older

The recommended starting dosage for pediatric liver transplant patients 3 months and older is 600 mg/m 2, administered twice daily. If well tolerated, the dose can be increased to a maintenance dosage of 900 mg/m 2administered twice daily (maximum total daily dose of 3 g or 15 mL of the oral suspension). The dose may be individualized based on clinical assessment.

Dosage Modifications: Patients with Renal Impairment, Neutropenia

Renal Impairment No dosage modifications are needed in kidney transplant patients with delayed graft function postoperatively. In kidney transplant patients with severe chronic impairment of the graft (GFR <25 mL/min/1.73 m 2), do not administer doses of MYHIBBIN greater than 1 g twice a day. These patients should be carefully monitored [ see Clinical Pharmacology (12.3)].

Neutropenia

If neutropenia develops (ANC <1.3 x 10 3/µL), dosing with MYHIBBIN should be interrupted or reduced, appropriate diagnostic tests performed, and the patient managed appropriately.